FDA Oncology Announcements

Announcements Trials

CXCR4 inhibitor × Lymphoid × Clear all

Conditions

Lymphoid 1 Plasma cell 1

Drug Classes

Anti-CD20 24 BTK inhibitor 17 Anti-CD19 CAR T-cell 15 Nitrogen mustard 8 Anti-CD30 ADC 7 Immunomodulatory drugs (IMiDs) 7 Anti-CD20-CD3 bispecific 5 Asparagine-specific enzyme 5 Bcl-2 inhibitor 5 Anti-CD19-CD3 bispecific 4 Anti-PD-1 4 PI3K delta inhibitor 4 Anti-CD19 3 Bcr-Abl inhibitor 3 HDAC inhibitor 3 Anti-CD22 ADC 2 Anti-CD79B ADC 2 EZH inhibitor 2 XPO1 inhibitor 2 ALK inhibitor 1 Anthracycline 1 Anti-CCR4 1 Anti-CD19 ADC 1 Anti-CD22 immunotoxin 1 Anti-IL-2R immunotoxin 1 Anti-IL-6 1 Antifolate 1 CXCR4 inhibitor 1 FGFR inhibitor 1 KMT2A inhibitor 1 Proteasome inhibitor 1 Purine analog 1 Vinca alkaloid 1

1 Announcement

Plerixafor

Drug: Mozobil (plerixafor) · CXCR4 inhibitor
Conditions: LymphoidPlasma cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡